Consensus statement. Corticosteroid therapy in ENT in the context of the COVID-19 pandemic |
| |
| Affiliation: | 1. Department of otorhinolaryngology, head and neck surgery, Lariboisière university hospital, AP–HP, Paris, France;2. Department of otorhinolaryngology, head and neck surgery, Lille university hospital, Lille, France;3. Department of otorhinolaryngology, head and neck surgery, Nancy university hospital, Nancy, France;4. Department of otorhinolaryngology, head and neck surgery, Necker hospital for sick children, AP–HP, Paris, France;5. Department of otorhinolaryngology, head and neck surgery, La Pitié-Salpêtrière university hospital, AP–HP, Paris, France;6. Department of otorhinolaryngology, head and neck surgery, Lyon south university hospital, Lyon, France;7. Department of otorhinolaryngology, head and neck surgery, Bicêtre university hospital, AP–HP, Le Kremlin Bicêtre, France;8. Department of otorhinolaryngology, head and neck surgery, La Conception university hospital, AP–HM, Marseille, France;9. Department of otorhinolaryngology, head and neck surgery, Hautepierre university hospital, Strasbourg, France;10. Department of otorhinolaryngology, head and neck surgery, CHU38 university hospital, Grenoble, France |
| |
| Abstract: | This consensus statement about the indications and modalities of corticosteroid treatment in the context of the COVID-19 pandemic was jointly written by experts from the French Association of Otology and Oto-Neurology (AFON) and from the French Society of Otorhinolaryngology, Head and Neck Surgery (SFORL). There is currently not enough data in favour of danger or benefit from corticosteroids in COVID-19, so until this matter is resolved it is advisable to limit their indications to the most serious clinical pictures for which it is well established that this type of treatment has a positive impact on the progression of symptoms. In Grade V and VI Bell's palsy according to the House-Brackmann grading system, a week's course of oral corticosteroids is recommended. Corticosteroid therapy is also recommended in cases of sudden hearing loss of more than 60 dB, either in the form of intratympanic injections or a week's course of oral medication. In rhinology, there is no indication for systemic corticosteroid therapy in the current situation. However, patients are advised to continue with their local corticosteroid therapy in the form of a nasal spray or by inhalation. Treatments with corticosteroid nasal sprays can still be prescribed if there is no alternative. Finally, systemic or local corticosteroid therapy is not indicated for bacterial ENT infections. |
| |
| Keywords: | COVID-19 SARS-CoV-2 Anosmia Prednisone Bell's palsy Sudden hearing loss |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
